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Abstract
Background: Xeroderma pigmentosum complementation group F (XPF or ERCC4) plays a key role in DNA repair that
protects against genetic instability and carcinogenesis. A series of epidemiological studies have examined associations
between XPF polymorphisms and cancer risk, but the findings remain inconclusive.
Methodology/Principal Findings: In this meta-analysis of 47,639 cancer cases and 51,915 controls, by searching three
electronic databases (i.e., MEDLINE, EMBASE and CNKI), we summarized 43 case-control studies from 29 publications on four
commonly studied polymorphisms of XPF (i.e., rs1800067, rs1799801, rs2020955 and rs744154), and we did not find
statistical evidence of any significant association with overall cancer risk. However, in stratification analyses, we found a
significant association of XPF-rs1799801 with a reduced cancer risk in Caucasian populations (4,845 cases and 5,556 controls;
recessive model: OR=0.87, 95% CI=0.76–1.00, P=0.049, P=0.723 for heterogeneity test, I
2=0). Further genotype-
phenotype correlation analysis showed that the homozygous variant CC genotype carriers had higher XPF expression levels
than that of the TT genotype carriers (Student’s t test for a recessive model: P=0.046). No publication bias was found by
using the funnel plot and Egger’s test.
Conclusion: This meta-analysis suggests a lack of statistical evidence for the association between the four XPF SNPs and
overall risk of cancers. However, XPF-rs1799801 may be associated with cancer risk in Caucasian populations, which needs to
be further validated in single large, well-designed prospective studies.
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Introduction
Nucleotide excision repair (NER) is the most versatile, well
studied DNA repair mechanism in humans, mainly responsible for
repairing bulky DNA damage, such as DNA adducts caused by
UV radiation, mutagenic chemicals, or chemotherapeutic drugs
[1]. The repair process includes excising and removing damaged
nucleotides and synthesizing to fill the resultant gap by using the
complementary DNA strand as a template [1]. Therefore, reduced
DNA repair capacity (DRC) may lead to genomic instability and
carcinogenesis, and genes involved in the NER pathway are
candidate cancer susceptibility genes [1–3]. NER involves at least
four steps (Figure 1A): (a) damage recognition by a complex of
bound proteins including XPC; (b) unwinding of the DNA by the
TFIIH complex that includes XPD; (c) removal of the damaged
single-stranded fragment by molecules including an ERCC1/XPF
complex; and (d) synthesis by DNA polymerases [4].
One of the NER genes, xeroderma pigmentosum complemen-
tation group F (XPF), also called excision repair cross-complimen-
tary group 4 (ERCC4), is located on chromosome 16p13.12,
contains 11 exons and spans approximately 28.2 kb (Figure 1B)
[5]. It is a key component involved in the 59 incision made during
NER [2]. The XPF protein consists of 916 amino acids, containing
an ERCC4 domain (Figure 1C) that is one of the nuclease family,
in which essential meiotic endonuclease 1 (EME1) acts as an
essential component of a Holliday junction resolvase to interact
with MUS81 [6,7]. The ERCC4 domain is also necessary for
forming a tight complex with ERCC1 as a structure-specific DNA
repair endonuclease responsible for the 59-primer incision during
DNA excision repair (Figure 1C) [8,9]. In addition to NER, this
complex is suggested to play a role in removal of DNA interstrand
cross-links (ICL) [10] and DNA double-strand breaks (DSB) as
well [11].
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e38606To date, a total of 580 single nucleotide polymorphisms (SNPs)
in the XPF gene have been reported according to the dbSNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?chooseRs=all&go=Go&locusId=2072), some of which have
been shown as susceptibility loci for several kinds of cancer,
including those of the breast, endometrium, and colorectum [12–
15]. For example, an important and frequent XPF polymorphism
– rs1800067 (Arg415Gln), which results in an arginine-to-
glutamine transition at codon 415 (Figure 1B), may affect protein
interactions, diminish the activity of the ERCC1/XPF complex
and alter genetic susceptibility to cancer [16]. The XPF-rs1799801
(Ser835Ser) polymorphism (Figure 1B), though not altering
amino acids, was reported to be a risk factor for cancer [17].
Another commonly studied XPF SNP, (rs2020955) is a serine-to-
proline transition at codon 662, which is less frequent but
potentially affecting the function of the gene. Interestingly, another
Figure 1. Structural characteristics and function of XPF as modified from KEGG and GeneBank database. (A) NER involves at least four
steps: (a) damage recognition by a complex of bound proteins including XPC, (b) unwinding of the DNA by the TFIIH complex that includes XPD, (c)
removal of the damaged single-stranded fragment by molecules including an ERCC1/XPF complex, and (d) synthesis by DNA polymerases; (B) The
XPF gene map labeled with 11 exons, and four polymorphisms that have been commonly studied for their associations with cancer risk (i.e.,
rs1800067, rs1799801, rs2020955 and rs744154); (C) The XPF protein consists of 916 amino acids, containing an ERCC4 domain. Abbreviation: NER,
nucleotide excision repair; KEGG, Kyoto Encyclopedia of Genes and Genomes.
doi:10.1371/journal.pone.0038606.g001
XPF Variants and Cancer Risk
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e38606commonly studied XPF SNP (rs744154) is located at intron 1, and
its functionality is unknown (Figure 1B). To date, associations of
these four SNPs with cancer risk have been investigated by a
number of reported studies [12–15,17–41], but the results are
inconclusive, partially because of a possible weak effect of the
polymorphisms on cancer risk or study design with a relatively
small sample size to detect such weak associations in each of the
published studies. Therefore, we performed a meta-analysis that
assemblies a large sample size to derive a more precise risk
estimate for the commonly studied XPF polymorphisms (each
investigated at least by four published studies) with an improved
statistic power to detect their associations with cancer risk.
Methods
Literature Search Strategy
We first used two electronic databases (MEDLINE and
EMBASE) to identify all case-control studies published to date
on an association between XPF polymorphisms and cancer risk
(the last search update on December 16, 2011, using the search
terms ‘‘XPF’’ or ‘‘ERCC4’’; ‘‘cancer’’, ‘‘neoplasia’’, ‘‘malignancy’’
or ‘‘carcinoma’’; ‘‘polymorphism’’ or ‘‘variant’’). To expand the
coverage of our searches, we further searched Chinese National
Knowledge Infrastructure (CNKI) database (http://www.cnki.net)
(1979–), using the terms ‘‘XPF’’ or ‘‘ERCC4’’; ‘‘cancer’’ in Chinese.
Additional published studies on this topic in the references of each
publication were also hand reviewed. We further contacted study
investigators to identify some unpublished or submitted studies.
Only studies with a full text article were included. The authors of
published papers were also contacted directly, if crucial data were
not reported in original papers. When more than one of the same
patient populations were included in different publications, only
the most recent or complete study with the largest sample size was
included in this meta-analysis.
Selection Criteria
Studies included in the current meta-analysis had to meet the
following criteria: evaluation of XPF polymorphisms and cancer
risk; more than three studies were available for a certain SNP;
written in English or Chinese; case-control study design; sufficient
information needed to estimate odds ratios (ORs) and their 95%
confidence intervals (CIs); and independent from other studies to
avoid double weighting in the estimates derived from the same
study. In addition, investigations in control subjects with cancer
patients or departure from Hardy-Weinberg equilibrium (HWE)
were also excluded from the final analysis.
Data Extraction
Two authors (STY and HJ) independently extracted data and
reached a consensus on all of the items. The following information
was extracted from each report: the first author, year of
publication, country of origin, ethnicity, cancer type, study type
(retrospective and prospective), control source [population-based
(PB), hospital-based (HB) and family-based (FB)], DNA source
(e.g., blood, lymphocytes, and buccal cells), and genotyping
methods, total numbers of cases and controls, minor allele
frequency (MAF) and numbers of cases and controls with the
wild-type, heterozygous and homozygous genotypes. For studies
including subjects of different racial descents and having complete
genotyping data for each race, data were extracted separately for
each ethnic group (categorized as Caucasian, African American,
Asian or others). When a study did not state the detailed
genotyping result for each ethnic group or if it was impossible to
separate participants according to the data presented, the sample
was termed as ‘‘mixed’’. If the numbers of genotyping methods in
a study were more than three and no detailed method information
was given, the methods were defined ‘‘pooled’’. Furthermore,
references involving different ethnic groups, different types of
cancer and different institutions were divided into multiple single
study samples for subgroup analyses.
Quantitative Data Synthesis
The numbers of cases and controls by the wild-type, heterozy-
gous and homozygous genotypes were collected from each study to
evaluate the risk of developing cancers (ORs and 95% CIs). We
further performed stratification analyses by cancer type (if one
cancer type was investigated in less than three studies, it would be
merged into the ‘‘other cancers’’ group), study type (retrospective
and prospective), ethnicity (Caucasian, African American, Asian or
others), control source (HB, PB and FB) and sample size (numbers
of cases ,500, 500–1000 and .1000).
HWE was evaluated for control subjects of each study, using the
goodness-of-fit x
2-test, and P,0.05 was considered representative
of departure from HWE. Crude ORs with 95% CIs were used to
assess the strength of associations between the XPF polymorphisms
and cancer risk. The pooled ORs were calculated by using
homozygous model (variant homozygous vs. wild-type) and
recessive model (homozygous vs. heterozygous + wild-type). For
each study, we estimated statistical power to detect an OR of 1.50
(for a risk effect) or its reciprocal 0.67 (for a protective effect), with
an a level equal to the observed P value [42]. The x
2-based Q test
was performed to assess between-study heterogeneity and consid-
ered significant if P,0.05 [43].
Heterogeneity was also quantified with the I
2 statistic, a value
that indicates what proportion of the total variation across studies
is beyond chance. Specifically, 0% indicates no observed
heterogeneity, and larger values show increasing heterogeneity
[44]. When P value of the heterogeneity test was $0.05, the fixed-
effects model, based on the Mantel-Haenszel method was used,
which assumes the same homogeneity of effect size across all
studies [45]. Otherwise, the random-effects model, based on the
DerSimonian and Laird method, was more appropriate, which
tends to provide wider 95% CIs as the results of the constituent
studies differ among themselves [46]. Subgroup analyses were also
performed by cancer type, ethnicity, control source and sample
size. To assess the effects of individual studies on the overall risk of
cancer, sensitivity analysis was performed by excluding each study
at a time individually and recalculating the ORs and 95% CIs.
Potential publication bias was estimated by the inverted funnel
plot, in which the standard error of log (OR) of each study was
plotted against its log (OR) [47], and an asymmetric plot suggests a
possible publication bias. Funnel plot asymmetry was assessed by
the method of Egger’s linear regression test, a linear regression
approach to measure funnel plot asymmetry on the natural
logarithm scale of the ORs [47]. The significance of the intercept
was determined by the t test as suggested by Egger, and P,0.05
was considered representative of statistically significant publication
bias [47]. If publication bias existed, the Duval and Tweedie
nonparametric ‘‘trim and fill’’ method was used to adjust for it
[48].
Genotype-phenotype Correlation Analysis
To evaluate biological plausibility of our findings, we used the
data on XPF polymorphism genotypes and XPF transcript
(mRNA) expression levels both available for 270 lymphoblastoid
cell lines by SNPexp online tool (http://app3.titan.uio.no/
biotools/help.php?app=snpexp), which provides a convenient
and platform-independent way to calculate and visualize the
XPF Variants and Cancer Risk
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of interest and gene expression levels [49]. The genotyping data
were from the international HapMap phase II release #23 dataset
(http://www.hapmap.org) consisting of 3.96 million SNPs that
were genotyped using genomic DNA from the 270 individuals
from four worldwide populations [CEU: 90 Utah residents with
ancestry from northern and western Europe; CHB: 45 unrelated
Han Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo;
YRI: 90 Yoruba in Ibadan, Nigeria] [50,51]. The data of gene
expression levels in the same 270 HapMap individuals were from
GENEVAR (GENe Expression VARiation, http://www.sanger.
ac.uk/resources/software/genevar/) and were detected by using
genome-wide expression arrays (47294 transcripts) from EBV-
transformed lymphoblastoid cell lines [52]. Student’s t test and
analysis of variance test were used to evaluate the differences in the
relative mRNA expression levels among different genotype groups.
All analyses were conducted by using STATA version 11.0 (Stata
Corporation, College Station, TX) and SAS version 9.1 (SAS
Institute, Cary, NC). All P values were two-sided with a
significance level of P,0.05.
Results
Flow of Included Studies
As showed in Figure 2, a total of 88 published and
unduplicated records from the MEDLINE and EMBASE
databases, 17 records from the CNKI database and one submitted
record were retrieved by using the key words mentioned in the
Methods, of which 39 studies examined the association of the
commonly studied XPF polymorphisms [i.e., rs1800067
(Arg415Gln, exon 8), rs1799801 (Ser835Ser, exon 11),
rs2020955 (Ser662Pro, exon10) and rs744154 (intron 1);
Figure 1B] with cancer risk. Among those 39 publications, four
[53–56] were excluded because their patient populations were
included in other studies [12,15,31], one case-control study was
excluded because control subjects were of cancer patients [57],
one was excluded because no variant allele was observed [58], one
study was excluded for departure of the genotype distribution from
HWE [33], and three was excluded because of unavailable data to
extract ORs and 95% CIs even after having contacted the authors
[59–61]. The remaining 29 publications of case-control studies
contained 43 case-control studies, with a total of 47,639 cancer
cases and 51,915 controls of different ethnicities for studying the
four polymorphisms.
Studies Characteristics
Table 1 lists the essential information for all studies, including
first author, year of publication, cancer type, country, ethnicity,
study type, source of control, numbers of cases and controls, MAF
of controls, statistical power, source of DNA and genotyping
methods, grouped by different polymorphisms. For the XPF-
rs1800067 SNP, the final analysis included nine breast cancer
studies [13,21,23,27,29,31,32], four colorectal cancer studies
[14,22,24,28], three cancer studies of head and neck [18,25,41],
two lung cancer studies [15,20], and five studies of other cancers
[12,19,26,30]. Overall, 17 studies used Caucasians, three used
African Americans, one used Latinos, and two used mixed ethnic
populations. There were 12, nine, one and one studies using PB,
HB, PB/HB and FB design, respectively. For the XPF-rs1799801
SNP, the final analysis included three prostate cancer studies
[19,34], three bladder cancer studies [33,35,39], two breast cancer
studies [17,37] and three studies of other cancers [12,36,38].
Among them, six studies used Caucasians, two used African
Americans, and three used Asians. Six studies were PB design and
five HB design. In addition, there were five and four studies having
investigated rs2020955 [27,30,33,34] and rs744154 SNPs [39,40],
respectively.
Almost all of the cases were histopathologically confirmed,
except for six studies [13,15,20,34,36,40]. Controls were mainly
matched with cases by age and/or other variables except for five
studies [22,24,26–28]. All the studies reached 50% power to detect
the associations between XPF polymorphisms and cancer risk,
except for five studies [19,26,27,39]. Blood and lymphocytes were
the most common source of DNA, and other sources included
buccal cells, buffy coat and mouthwash samples. PCR-based
methods were most commonly used in genotyping among these
studies.
Meta-analysis Results
Table 2 lists the main results of the meta-analysis for the four
polymorphisms in the XPF gene. Given that the xeroderma
pigmentosum (XP) syndromes caused by XP germ-line mutations
fit a recessive genetic model, in which heterozygotes are unaffected
[62], we tested the hypothesis that the XPF polymorphisms were
associated with overall cancer risk, assuming a recessive genetic
model (i.e., only the variant homozygous genotype was considered
the risk genotype).
For the XPF-rs1800067 SNP, we obtained genotyping data from
20 publications consisting of 14,632 cancer cases and 15,545
controls. As showed in Table 2, when all eligible studies were
pooled into the meta-analysis, we found that the XPF-rs1800067
polymorphism was not significantly associated with overall cancer
risk, with a statistical power of 98% (homozygous model:
OR=1.21, 95% CI=0.73–1.99, P=0.020 for heterogeneity test,
I
2=45.2%; recessive model: OR=1.20, 95% CI=0.73–1.98,
P=0.022 for heterogeneity test, I
2=44.6%). In stratification
analyses by cancer type, ethnicity, source of controls or sample
size, there was no significant association of XPF-rs1800067 SNP
with cancer risk in any of the subgroups (Table 2, Figure 3A, B).
For the XPF-rs1799801 SNP, genotyping data of 5,979 cancer
cases and 6,633 controls were obtained from 10 publications.
Overall, the XPF-rs1799801 polymorphism was not significantly
associated with cancer risk (homozygous model: OR=0.91, 95%
CI=0.79–1.04, P=0.783 for heterogeneity test, I
2=0; recessive
model: OR=0.89, 95% CI=0.78–1.01, P=0.764 for heteroge-
neity test, I
2=0;Table 2). However, in stratification analyses, we
found a significant association of the XPF-rs1799801 SNP with a
reduced cancer risk in Caucasian populations, with a statistical
power of 100% (4,845 cases and 5,556 controls; recessive model:
OR=0.87, 95% CI=0.76–1.00, P=0.049, P=0.723 for hetero-
geneity test, I
2=0; Table 2, Figure 4A, B). After stratified by
cancer type, source of controls or sample size, no additional
significant association of the XPF-rs1799801 SNP with overall
cancer risk was found in any of the subgroups.
For XPF-rs2020955 and rs744154 SNPs, a total of 2,835 cancer
cases and 2,670 controls and a total of 29,328 cancer cases and
31,999 controls were included, respectively. No significant
association of these two SNPs with cancer risk was found in
recessive models (OR=1.07, 95% CI=0.72–1.60, P=0.897 for
heterogeneity test, I
2=0%, statistical power=97%; and
OR=0.98, 95% CI=0.92–1.04, P=0.140 for heterogeneity test,
I
2=45.2%, statistical power=100%, respectively; Table 2).
Because a limited number of published studies for these two
polymorphisms were included, no further stratification analysis
was performed.
XPF Variants and Cancer Risk
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Substantial heterogeneities were observed among studies for the
association between the XPF-rs1800067 polymorphism and cancer
risk (homozygous model: x
2=31.02, df=17, P=0.020; recessive
model: x
2=30.66, df=17, P=0.022). Therefore, we used the
random-effects model that generated wider CIs. For the other
three SNPs of the XPF gene (i.e., rs1799801, rs2020955 and
rs744154), no heterogeneity was found among studies or in
stratification analyses in recessive models (x
2=6.58, df=10,
P=0.764; x
2=0.02, df=1, P=0.897; and x
2=5.47, df=3,
P=0.140, respectively), and the fixed-effects model was per-
formed. The leave-one-out sensitivity analysis indicated that no
single study changed the pooled ORs qualitatively (data not
shown).
Publication Bias
The shapes of the funnel plots seemed symmetrical, and Egger’s
test suggested that there was no publication bias for studies of XPF-
rs1800067, rs1799801, rs2020955 and rs744154 SNPs’ associa-
tions with cancer risk in the current meta-analysis [recessive
model: P=0.445, 0.205, no value (i.e., Only two studies were
included when assumed a recessive genetic model, which caused
no value for the Egger’s test) and 0.663, respectively]. These
findings indicated that bias from publications, if any, might not
have a significant effect on the results of our meta-analysis for the
association between the four commonly studied XPF polymor-
phisms and overall cancer risk.
Correlation Between XPF-rs1799801 Genotypes and XPF
Transcript Expression Levels
Given that the XPF-rs1799801 SNP, which is located in exon
11, showed a significant association with cancer risk in Caucasian
populations, we used the SNPexp online tool to further evaluate
biological plausibility underlying the observed association by
exploring the correlation between the known XPF-rs1799801
genotypes and the relative expression levels of XPF transcripts. For
the 270 individuals whose genotyping and expression data were
available for the analysis, there were 172 TT carriers, 77 CT
carriers and 15 CC carriers (Figure 5A). Homozygous variant
CC genotype carriers had significantly higher XPF transcript
expression levels than those of wild-type TT carriers and TT+CT
carriers (Student’s t test, P=0.032 and 0.046, respectively;
Figure 5A, B). For the 90 Caucasian subjects, 53 TT carriers,
27 CT carriers and seven CC carriers were observed, but the
difference in XPF transcript expression levels between the variant
CC genotype, TT and TT+CT genotypes did not reach statistical
significance (Student’s t test, P=0.063 and 0.127, respectively;
Figure 5C, D).
Discussion
The mechanisms underlying carcinogenesis are multifactorial,
and a single genetic variant is usually insufficient to predict risk of
cancer, a complex disease phenotype in nature [63]. However, it is
likely that suboptimal DNA repair may have a non-specific effect
on risk of cancer that originated from DNA damage and
subsequent mutation fixation [64]. In this meta-analysis, we
Figure 2. Flow diagram of included studies for this meta-analysis.
doi:10.1371/journal.pone.0038606.g002
XPF Variants and Cancer Risk
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PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e38606summarized all available published data on associations between
commonly studied XPF polymorphisms and overall cancer risk.
Because germ-line mutations in XP genes cause some rare
inherited human syndromes, such as XP, cockayne syndrome
(CS) and trichothiodystrophy (TTD) following a recessive genetic
model [65–67], in which mutant homozygotes manifest the disease
Figure 3. Forest plot of cancer risk associated with the XPF-rs1800067 polymorphism stratified by ethnicity. (A) AA vs. GG in a
homozygous model and (B) AA vs. (AG+GG) in a recessive model by the random-effects for each of the 23 published studies. For each study, the
estimates of OR and its 95% CI were plotted with a box and a horizontal line. The symbol filled diamond indicates pooled OR and its 95% CI. No
significant association between the XPF-rs1800067 polymorphism and cancer risk was found.
doi:10.1371/journal.pone.0038606.g003
Figure 4. Forest plot of cancer risk associated with the XPF-rs1799801 polymorphism stratified by ethnicity. (A) CC vs. TT in a
homozygous model and (B) CC vs. (CT+TT) in a recessive model by the fixed-effects for each of the 11 published studies. For each study, the estimates
of OR and its 95% CI were plotted with a box and a horizontal line. The symbol filled diamond indicates pooled OR and its 95% CI. A significant
association of the XPF-rs1799801 SNP with a borderline cancer risk in Caucasian populations was found (4845 cases and 5556 controls; recessive
model: OR=0.87, 95% CI=0.76–1.00, P=0.049, P=0.723 for heterogeneity test, I
2=0).
doi:10.1371/journal.pone.0038606.g004
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PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e38606but the heterozygotes have a normal phenotype [62]. Therefore,
we assessed the associations between XPF polymorphisms and
cancer risk by assuming the XP recessive genetic model.
In this meta-analysis of associations between the four commonly
studied XPF polymorphisms and cancer risk under the recessive
genetic model, we did not find statistical evidence of associations of
the XPF-rs1800067, rs2020955 and rs744154 SNPs with cancer
risk, nor in stratification analyses. One possible explanation is that
these variants, especially of rs1800067 and rs744154, are likely to
be low-penetrance SNPs with a very weak effect that needs a much
larger sample size to detect [63]. Alternatively, these SNPs may
not have any effect on cancer risk, given this meta-analysis of
pooling all available studies had included a relatively large sample
size. There were two obvious differences between our analysis and
another recent meta-analysis of the association between the XPF-
rs1800067 SNP and breast cancer risk by Ding [68]. Firstly, Ding
Figure 5. The relative expression levels of XPF transcripts by the known XPF-rs1799801 genotypes in 270 HapMap subjects.
Homozygous variant CC genotype carriers showed a significant increased trend of XPF mRNA expression levels in overall populations, compare to (A)
wild-type TT genotype ones, and (B) recessive reference TT+CT genotype ones (Student’s t test, P=0.032 and 0.046, respectively); but the difference
in XPF transcript expression levels between the variant CC genotype and (C) wild-type TT genotype, and (D) TT+CT genotypes did not reach statistical
significance (Student’s t test, P=0.063 and 0.127, respectively).
doi:10.1371/journal.pone.0038606.g005
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cancer risk, whereas, our analysis included four XPF SNPs for their
associations with risk of several cancers with a much larger sample
size, which provided a more precise assessment of the associations
with risk of cancers, including breast, colorectal and other cancers.
Secondly, in the present meta-analysis, we also included one more
breast cancer study with 1,145 cases and 1,142 controls of
Caucasians for the risk association with XPF-rs1800067 [13].
Furthermore, the subjects from Crew’s study of 1,018 breast
cancer cases and 1,065 controls were predominantly of Caucasians
[21], leading to a sample size of more than 2,000 Caucasians
added to our new analysis, which increased the weight of
Caucasians and study power, although we did not find evidence
of any association between the XPF-rs1800067 SNP and overall
risk of cancers, including breast cancer.
For the XPF-rs1799801 SNP, a total of 5,979 cancer cases and
6,633 controls from 10 independent publications were included.
Apparently, studies of these Caucasian populations were quite
homogenous, compared with those of XPF-rs1800067 SNP.
Although we did not find any significant association with cancer
risk, in the stratification analyses, we did find a significant
association between the XPF-rs1799801 SNP and cancer risk in
Caucasian populations but not in other ethnicities. Further
genotype-phenotype correlation analysis showed that homozygous
variant CC genotype carriers had significantly increased XPF
transcript expression levels in all 270 subjects but not in the 90
Caucasians. This inconsistency is likely due to the reduction in the
sample size for Caucasian subjects (n=90), compared with the
overall effect by genotypes of all 270 subjects. Another reason
could be the heterogeneity of studies included in the analysis of
overall risk, such as different weights of ethnicities included in the
overall analysis, which may have confounded the results. For
example, for the other two ethnicities, especially African Amer-
ican, less than 500 individuals were included with an insufficient
statistical power (44.4%) to detect such an association, which
might cause a bias in the combined analysis of the association
between XPF-rs1799801 and cancer risk for all populations.
The XPF rs1799801 is highly linked with several other
potentially functional SNPs of XPF, such as the rs2276466 SNP,
which is located at the 39-untranslated region (UTR) of XPF.B y
using the same HapMap and GENEVAR datasets online, in the
overall 270 individuals, there were 175 CC carriers, 77 CG
carriers and 16 GG carriers for the XPF-rs2276466 SNP.
Homozygous variant GG genotype carriers had a significantly
higher XPF transcript expression levels than that of wild-type CC
carriers and CC+CG carriers (Student’s t test, P=0.021 and
0.034, respectively). Although the function of the XPF-rs2276466
SNP has not been characterized yet, it is well known that variants,
located in the 3?-UTR, particularly at a miRNA binding site, may
affect mRNA expression levels [69]. Therefore, additional
explanation for the correlation of XPF-rs1799801 SNP with XPF
mRNA expression levels may be that some synonymous SNPs
appear to act as functional variants in the regulation of gene
expression as if they were functional, because of their linkage with
other untyped functional SNPs. Additionally, several studies have
found that some synonymous SNPs significantly associated with
disease phenotypes or traits can be functional by themselves [70],
which is because such ‘‘silent’’ polymorphisms may produce a
protein product with similar but different structures that may lead
to ribosome stalling and alteration of protein folding [71]. Such a
hypothesis remains to be tested in future mechanistic studies.
There are several limitations in this meta-analysis, especially for
generalization to the general population. First, the quality of the
studies included was not optimal. Two studies [14,15] did not
clearly state the ethnicity for genotyping data, and the other two
[15,40] mixed two sources of controls (PB and HB) and did not
clearly state the respective genotyping data, which could cause
some bias in our estimates. Secondly, obvious heterogeneity across
studies for the XPF-rs1800067 SNP, which might result from
inclusion of imbalanced ethnic groups and types of cancer, existed
in overall and some subgroup analyses. Third, for some SNPs (i.e.,
XPF-rs2020955 and rs744154) and a certain subgroup (i.e.,
African Americans and Asians), the numbers of studies and
individual sample sizes were relatively small, having no enough
statistical power to detect a weak association. Fourth, our results
were based on unadjusted estimates, because not all published
studies presented with adjusted estimates or when they did, the
estimates were not adjusted by the same potential confounders. A
more precise analysis should be conducted, if individual data were
available, which would allow for the adjustment by other
covariants, including age, ethnicity, smoking status, drinking
status, environmental factors, and other lifestyles. Finally, although
one unpublished study was included in this meta-analysis, many
unpublished data may have not been included in the analysis,
potentially causing a bias in our meta-analysis.
Overall, our meta-analysis did not provide statistical evidence
for an association between the four commonly studied SNPs of the
XPF gene and overall risk of several human cancers, but we did
find a significant association between the homozygous variant CC
genotype of the XPF-rs1799801 SNP and a reduced cancer risk in
Caucasian populations. Further genotype-phenotype correlation
analysis indicated that the XPF-rs1799801 homozygous variant
CC genotype carriers showed an increased trend of XPF
expression levels. However, single large, well-designed prospective
studies are needed to confirm these findings.
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